JP2013544887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544887A5 JP2013544887A5 JP2013543255A JP2013543255A JP2013544887A5 JP 2013544887 A5 JP2013544887 A5 JP 2013544887A5 JP 2013543255 A JP2013543255 A JP 2013543255A JP 2013543255 A JP2013543255 A JP 2013543255A JP 2013544887 A5 JP2013544887 A5 JP 2013544887A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- laquinimod
- medicament
- patient
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 70
- 229960004577 laquinimod Drugs 0.000 claims description 70
- 201000006417 multiple sclerosis Diseases 0.000 claims description 12
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 9
- 230000006866 deterioration Effects 0.000 claims description 9
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000000977 initiatory effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 230000009223 neuronal apoptosis Effects 0.000 claims description 4
- 230000006764 neuronal dysfunction Effects 0.000 claims description 4
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 25
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010016256 fatigue Diseases 0.000 claims 3
- 230000003190 augmentative effect Effects 0.000 claims 1
- 230000005182 global health Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 230000002411 adverse Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42074210P | 2010-12-07 | 2010-12-07 | |
| US61/420,742 | 2010-12-07 | ||
| US201161542996P | 2011-10-04 | 2011-10-04 | |
| US61/542,996 | 2011-10-04 | ||
| PCT/US2011/063460 WO2012078591A1 (en) | 2010-12-07 | 2011-12-06 | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016251360A Division JP2017095476A (ja) | 2010-12-07 | 2016-12-26 | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013544887A JP2013544887A (ja) | 2013-12-19 |
| JP2013544887A5 true JP2013544887A5 (enExample) | 2015-05-07 |
Family
ID=46162796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543255A Pending JP2013544887A (ja) | 2010-12-07 | 2011-12-06 | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用 |
| JP2016251360A Pending JP2017095476A (ja) | 2010-12-07 | 2016-12-26 | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016251360A Pending JP2017095476A (ja) | 2010-12-07 | 2016-12-26 | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20120142730A1 (enExample) |
| EP (1) | EP2648732A4 (enExample) |
| JP (2) | JP2013544887A (enExample) |
| KR (1) | KR20130124518A (enExample) |
| CN (1) | CN103260624B (enExample) |
| AU (2) | AU2011338647A1 (enExample) |
| BR (1) | BR112013014061A2 (enExample) |
| CA (1) | CA2820586A1 (enExample) |
| CL (1) | CL2013001602A1 (enExample) |
| EA (1) | EA201390827A1 (enExample) |
| IL (1) | IL250726A0 (enExample) |
| MX (1) | MX2013006464A (enExample) |
| NZ (1) | NZ611628A (enExample) |
| PE (1) | PE20140872A1 (enExample) |
| PH (1) | PH12013501193A1 (enExample) |
| SG (2) | SG190449A1 (enExample) |
| UA (1) | UA111959C2 (enExample) |
| WO (1) | WO2012078591A1 (enExample) |
| ZA (1) | ZA201304237B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1937642B1 (en) * | 2005-10-19 | 2014-09-10 | Teva Pharmaceutical Industries Ltd | Crystals of laquinimod sodium, and process for the manufacture thereof |
| EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| RS54707B1 (sr) * | 2009-07-30 | 2016-08-31 | Teva Pharmaceutical Industries Ltd. | Tretman kronove bolesti lakvinimodom |
| PL3064206T3 (pl) | 2009-08-10 | 2020-02-28 | Active Biotech Ab | Leczenie choroby Huntingtona z zastosowaniem lakwinimodu |
| NZ602510A (en) * | 2010-03-03 | 2014-11-28 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
| SG183513A1 (en) * | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| KR20140138725A (ko) | 2012-02-16 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| IN2015DN03219A (enExample) * | 2012-09-27 | 2015-10-02 | Teva Pharma | |
| EA201590726A1 (ru) * | 2012-10-12 | 2015-10-30 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для уменьшения таламического поражения при рассеянном склерозе |
| HK1212936A1 (zh) | 2012-11-07 | 2016-06-24 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| SG11201505818WA (en) * | 2013-02-15 | 2015-08-28 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| HK1220125A1 (zh) | 2013-03-14 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德的透皮配方 |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| AU2014364447A1 (en) * | 2013-12-20 | 2016-08-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay Huntington's disease progression |
| US20160331742A1 (en) * | 2014-01-17 | 2016-11-17 | Teva Pharmaceutical Industries, Ltd. | Treatment of crohn's disease using low doses of laquinimod |
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
| US10537566B2 (en) | 2014-10-16 | 2020-01-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| CN112770748A (zh) * | 2018-10-09 | 2021-05-07 | 美迪诺亚公司 | 异丁司特和干扰素-β的组合及其使用方法 |
| CA3145269A1 (en) * | 2019-07-22 | 2021-01-28 | Michel BURCKLEN | Use of ponesimod for the treatment of multiple sclerosis |
| CN110688373A (zh) * | 2019-09-17 | 2020-01-14 | 杭州绿度信息技术有限公司 | 一种基于逻辑回归的offset方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560100B2 (en) * | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| BRPI0713694A2 (pt) * | 2006-06-12 | 2012-10-30 | Teva Pharma | composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica |
| PT2653873T (pt) * | 2007-02-08 | 2022-07-26 | Biogen Ma Inc | Composições e utilizações para o tratamento de esclerose múltipla |
| CN107308162A (zh) * | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | 利用拉喹莫德治疗多发性硬化 |
-
2011
- 2011-12-06 UA UAA201308448A patent/UA111959C2/uk unknown
- 2011-12-06 EA EA201390827A patent/EA201390827A1/ru unknown
- 2011-12-06 NZ NZ611628A patent/NZ611628A/en not_active IP Right Cessation
- 2011-12-06 MX MX2013006464A patent/MX2013006464A/es unknown
- 2011-12-06 WO PCT/US2011/063460 patent/WO2012078591A1/en not_active Ceased
- 2011-12-06 AU AU2011338647A patent/AU2011338647A1/en not_active Abandoned
- 2011-12-06 PH PH1/2013/501193A patent/PH12013501193A1/en unknown
- 2011-12-06 SG SG2013042403A patent/SG190449A1/en unknown
- 2011-12-06 JP JP2013543255A patent/JP2013544887A/ja active Pending
- 2011-12-06 PE PE2013001357A patent/PE20140872A1/es not_active Application Discontinuation
- 2011-12-06 BR BR112013014061A patent/BR112013014061A2/pt not_active Application Discontinuation
- 2011-12-06 CA CA2820586A patent/CA2820586A1/en not_active Abandoned
- 2011-12-06 EP EP11846599.6A patent/EP2648732A4/en not_active Withdrawn
- 2011-12-06 CN CN201180060414.8A patent/CN103260624B/zh not_active Expired - Fee Related
- 2011-12-06 KR KR1020137017362A patent/KR20130124518A/ko not_active Ceased
- 2011-12-06 SG SG10201509831XA patent/SG10201509831XA/en unknown
- 2011-12-06 US US13/312,284 patent/US20120142730A1/en not_active Abandoned
-
2013
- 2013-06-05 CL CL2013001602A patent/CL2013001602A1/es unknown
- 2013-06-10 ZA ZA2013/04237A patent/ZA201304237B/en unknown
-
2016
- 2016-12-26 JP JP2016251360A patent/JP2017095476A/ja active Pending
-
2017
- 2017-02-22 IL IL250726A patent/IL250726A0/en unknown
- 2017-03-28 AU AU2017202055A patent/AU2017202055A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544887A5 (enExample) | ||
| JP2014521658A5 (enExample) | ||
| JP2016523862A5 (enExample) | ||
| JP2012006970A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2013522230A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| JP6731915B2 (ja) | 多発性硬化症治療用のシポニモドとラキニモドを含む組み合わせ | |
| JP2013535437A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| CA2549801A1 (en) | Use of treprostinil to improve kidney functions | |
| JP2013521303A5 (enExample) | ||
| JP2013056911A (ja) | 運動障害の予防および／または治療剤 | |
| JP2017525771A (ja) | 体重と体脂肪減少に用いられる組成物およびその医薬品と使用 | |
| JP2018537513A5 (enExample) | ||
| JP2022507533A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| JP2013501049A5 (enExample) | ||
| JP2008538582A (ja) | 精神病性障害の治療または予防のための新規の治療的組み合わせ | |
| JP2016537432A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| JP2019531286A5 (enExample) | ||
| JP2015521647A5 (enExample) | ||
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 |